Efficacy and cosmetic outcomes of high-dose-rate brachytherapy in the treatment of nasal carcinomas: a retrospective analysis

Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy

Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery

Successful treatment of squamous cell carcinoma with intralesional methotrexate

2022-LBA-841-ESGO Cosmetic outcome and psychosexual distress after treatment for vulvar intraepithelial neoplasia

Innovative Widefield Volumetric Arc Radiation Therapy (VMAT) Approach to Simultaneously Treat Extensive Skin Field Cancerization (ESFC) + In-Field Keratinocyte Carcinoma (KC) in Australian Patients: Report with 12 Month Follow-Up

Photodynamic therapy (PDT) is a relatively new method of treating skin cancers. This prospective study highlights the use of PDT in the management of basal cell carcinomas (BCCs) and T1N0 cutaneous squamous cell carcinomas (SCCs) involving the periorbital area. Surface illumination PDT was offered under local anaesthesia. mTHPC was administered intravenously. A single-channel 652nm diode laser was used for illumination, and light was delivered at 20J/cm2 per site. Lesion response evaluation was carried out according to response evaluation criteria in solid tumours (RECIST). After the first round of treatment, all cutaneous T1N0 SCC patients had complete response (CR) and continued to be in remission until last clinic review. For BCC patients, 12/14 patients had CR. The two remaining patients underwent a second round of treatment and also achieved a CR. All BCC patients were in remission at the last clinic review. Using visual analogue scale (VAS), 15 patients reported that this treatment gave them "excellent" cosmetic outcome (VAS 9-10). Photodynamic therapy achieved high efficacy in the treatment of periorbital BCCs and cutaneous SCCs with greatly reduced morbidity and disfigurement.

Twenty-year Experience in the Management of Anal Carcinoma with Interstitial Brachytherapy

Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial

Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma

Acute and Late Genitourinary Toxicity Among Patients Receiving Vaginal High Dose Rate Interstitial Brachytherapy

OBJECTIVE To determine the clinical features, treatment, and outcomes of treatment for oral and cutaneous squamous cell carcinoma (SCC) in avian species. DESIGN Retrospective case series with nested cohort study. ANIMALS 87 client-owned birds of various species with histologically confirmed SCC of the skin or oral cavity. PROCEDURES Clinicians entered case information through an online survey tool. Data were collected regarding patient signalment, concurrent conditions, treatments, adverse effects, and clinical outcomes. Relationships were examined between complete excision and partial or complete response. Survival analysis was performed to compare outcomes among groupings of therapeutic approaches. RESULTS Only 7 of 64 (11%) birds for which full outcome data were available had complete remission of SCC; 53 (83%) had progressive disease, were euthanized, or died of the disease. The unadjusted OR for partial or complete response following complete tumor excision (vs other treatment approaches) was 6.9 (95% confidence interval [CI], 1.8 to 25.8). Risk of death was 62% lower (hazard ratio, 0.38; 95% CI, 0.19 to 0.77) for birds that underwent complete excision versus conservative treatment. Median survival time from initial evaluation for birds receiving complete excision was 628 days (95% CI, 210 to 1,008 days), compared with 171 days (95% CI, 89 to 286 days) for birds receiving monitoring with or without conservative treatment. Birds receiving any other additional treatment had a median survival time of 357 days (95% CI, 143 to 562 days). CONCLUSIONS AND CLINICAL RELEVANCE For birds with SCC, complete excision was the only treatment approach significantly associated with complete or partial response and increased survival time.

BackgroundThe study aimed to assess the effect of High Dose Rate (HDR) Interstitial Brachytherapy when used alone or in combination with External Beam Radiotherapy (EBRT), in early and locally advanced squamous cell carcinoma of buccal mucosa.Materials and methodsThirty three patients with histologically proven squamous cell carcinoma of the buccal mucosa received high dose rate interstitial brachytherapy either as primary treatment or as a boost from November 2008 to April 2013. Stage I patients received interstitial brachytherapy alone to a dose of 38.50 Gy, 3.5 Gy per fraction, twice daily at six hours apart for 11 fractions. Stage II patients received EBRT to a dose of 50 Gy in 25 fractions of two Gy each followed by brachytherapy boost to 21 Gy, 3.5 Gy per fraction, twice daily at six hours apart for six fractions. Stage III patients received the same radiotherapy schedule (i.e., same EBRT & Brachytherapy schedule) and with addition of Injection Cisplatin 70 mg/m2 in three divided doses every three weeks along with EBRT.ResultsFollow up ranged from 12 to 60 months, median follow up was 26 months. Complete response was observed in 28 patients. Five patients had residual disease and were referred for surgical salvage. One patient died of disease progression. Stage I patients had 100% local control, whereas Stage II and Stage III patients had 84.6% and 80% local control respectively.ConclusionHDR Interstitial Brachytherapy used either as a primary treatment modality or as a boost in buccal mucosal cancers provides results comparable to that of surgery, with the advantages of organ preservation, better cosmetic and functional outcomes.

Interstitial brachytherapy for periocular nonmelanoma skin cancers: Impact on organ and function preservation

PurposeHigh-dose-rate (HDR) brachytherapy is a promising treatment modality for organ and function preservation in lip and oral cavity cancers. This study aims to describe the technique and assess clinical outcomes of HDR interstitial brachytherapy in patients diagnosed with lip and buccal mucosa cancer treated in a comprehensive cancer center.Materials and MethodsWe conducted a retrospective analysis of six lip and four buccal mucosa cancer patients with a median age of 69 years (range, 37 to 90) and equal gender distribution, who underwent exclusive interstitial brachytherapy during the study period from May 2019 to December 2024. All procedures were performed under local anesthesia. Most patients were treated with HDR brachytherapy with a total dose of 40 Gy in 10 fractions over 5 days. Patient characteristics, treatment parameters, cosmetic and functional outcomes, and toxicity were assessed.ResultsAll patients in this cohort achieved local control and remained in remission at the treatment site throughout the follow-up period. The median duration of follow-up was 29 months (range, 16 to 68). Cosmetic outcomes were rated as good in most of the patients. Any acute and late toxicities experienced were manageable; the most severe acute toxicity observed was grade 3, with late toxicity reaching grade 2.ConclusionFavorable tumor control, good aesthetic results with manageable toxicity, and the minimally invasive approach highlight interstitial brachytherapy as a compelling single treatment modality for eligible patients with lip and buccal mucosa cancer, particularly in older individuals with significant comorbidities.

Although surgery is the treatment of choice for Bowen disease (BD) and cutaneous squamous cell carcinoma (cSCC), nonsurgical treatments such as photodynamic therapy (PDT) may be preferred for select tumors. Previous meta-analysis have failed to gather strong evidence to recommend PDT. This study evaluates the effectiveness of PDT in the treatment of cSCC and BD for clearance rate (CR) after 1 year. A literature search of studies of biopsy-proven BD and cSCC treated with PDT was performed. Pooled CRs were estimated. Subgroup analyses were performed based on follow-up, treatment regimen, lesion size, and site. Forty-three studies were included, enrolling 1943 BD lesions and 282 SCC lesions. Pooled CRs for BD and SCC were 76% (95% CI: 71%-80%; I2 = 78.9%) and 51% (95% CI: 35%-66%; I2 = 85.7%), respectively. Our findings support the selective use of PDT for BD; however, patients should be advised of potential for recurrence. Although PDT can be used for certain cases of cSCC, the high rate of treatment failure necessitates close surveillance for residual or recurrent disease. Further studies are needed to justify the usage of PDT in the treatment of BD and cSCC.